Published in World J Gastroenterol on March 14, 2006
Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C. Psychosomatics (2009) 1.00
The ongoing impacts of hepatitis c--a systematic narrative review of the literature. BMC Public Health (2012) 0.85
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol (2012) 0.84
Psychological Reactions among Patients with Chronic Hepatitis B: a Qualitative Study. J Caring Sci (2016) 0.77
The psyche and the gut. World J Gastroenterol (2007) 0.77
Perceived risk for severe outcomes and drinking status among drug users with HIV and Hepatitis C Virus (HCV). Addict Behav (2016) 0.75
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology (1994) 9.86
Natural history of chronic hepatitis C. Hepatology (2002) 7.70
Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev (1989) 4.72
Scaling of life events. Arch Gen Psychiatry (1971) 3.38
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology (1999) 2.67
The impact of diagnosis of hepatitis C virus on quality of life. Hepatology (1999) 2.32
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res (2000) 2.04
Hepatitis C virus-infected patients report communication problems with physicians. Hepatology (2004) 1.95
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology (1999) 1.84
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology (1997) 1.55
Pain experienced during percutaneous liver biopsy. Hepatology (1999) 1.52
Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology (2005) 1.49
"They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med (2003) 1.47
Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology (2002) 1.47
Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res (2000) 1.32
Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol (2002) 1.28
Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome. Gastroenterology (2004) 1.24
Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci (1996) 1.20
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology (2004) 1.18
Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics (2000) 1.16
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat (1999) 1.16
Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci (1997) 1.15
Hepatitis C virus and depression in drug users. Am J Gastroenterol (1998) 1.07
Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci (1997) 1.04
Hepatitis C and depression. Depress Anxiety (1998) 1.04
Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol (2002) 0.95
Reduced quality of life in hepatitis C--is it all in the head? J Hepatol (2002) 0.88
Blood pressure estimation and beliefs among normotensives and hypertensives. Health Psychol (1988) 0.81
Symptom schemata in chronic respiratory patients. Health Psychol (1991) 0.80
Quality of life issues in hypertension: consequences of diagnosis and considerations in management. Am Heart J (1988) 0.79
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology (2010) 3.22
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology (2011) 2.54
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol (2006) 2.37
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology (2012) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol (2011) 1.79
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol (2010) 1.70
Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology (2013) 1.64
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int (2008) 1.62
Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis (2003) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology (2009) 1.55
Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS (2002) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant (2002) 1.48
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry (2005) 1.41
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology (2006) 1.34
Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl (2005) 1.28
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol (2009) 1.18
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med (2013) 1.02
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis (2004) 0.99
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int (2009) 0.97
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl (2006) 0.96
Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol (2002) 0.95
Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol (2008) 0.94
Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study. World J Gastroenterol (2006) 0.93
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology (2011) 0.92
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int (2014) 0.90
Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. J Gerontol A Biol Sci Med Sci (2006) 0.89
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol (2009) 0.89
Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol (2010) 0.88
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology (2006) 0.88
Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles. Psychosomatics (2005) 0.88
Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. Gastroenterol Clin Biol (2007) 0.87
Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol (2005) 0.86
Remission of protein-losing enteropathy after nodal lymphoma treatment in a patient with primary intestinal lymphangiectasia. Eur J Gastroenterol Hepatol (2005) 0.84
Impact of retirement on risky driving behavior and attitudes towards road safety among a large cohort of French drivers (the GAZEL cohort). Scand J Work Environ Health (2008) 0.84
Coping and adapting to breast cancer: a six-month prospective study. Bull Cancer (2006) 0.83
Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther (2009) 0.83
Hepatic Steatosis, Carbohydrate Intake, and Food Quotient in Patients with NAFLD. Int J Endocrinol (2013) 0.82
Ethanol perfusion increases the yield of oxidative phosphorylation in isolated liver of fed rats. Biochim Biophys Acta (2002) 0.81
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol (2004) 0.81
Risk compensation: a male phenomenon? Results from a controlled intervention trial promoting helmet use among cyclists. Am J Public Health (2012) 0.81
Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int (2011) 0.81
Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. J Med Virol (2004) 0.81
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol (2011) 0.80
Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. Gastroenterol Clin Biol (2006) 0.80
Resveratrol plus ethanol counteract the ethanol-induced impairment of energy metabolism: ³¹P NMR study of ATP and sn-glycerol-3-phosphate on isolated and perfused rat liver. Pharmacol Res (2011) 0.79
Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur J Gastroenterol Hepatol (2004) 0.79
[Psychiatric disorders during treatment of chronic hepatitis C]. Gastroenterol Clin Biol (2005) 0.79
Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. Hepatogastroenterology (2013) 0.79
[Chronic hepatitis C: management of side effects of treatment]. Gastroenterol Clin Biol (2007) 0.78
Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins. J Med Virol (2005) 0.78
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2012) 0.77
Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. J Gastroenterol (2013) 0.77
Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol (2004) 0.77
Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. Viral Immunol (2005) 0.76
Gastric variceal bleeding uncovering a rare association of CREST syndrome, primary biliary cirrhosis, nodular regenerative hyperplasia and pulmonary hypertension. Eur J Gastroenterol Hepatol (2010) 0.76
Drug treatments for obesity. Lancet (2007) 0.75
Utility of self-reported mental health measures for preventing unintentional injury: results from a cross-sectional study among French schoolchildren. BMC Pediatr (2014) 0.75
Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol (2006) 0.75
Hepatitis C virus cure as motivation for alcohol withdrawal? Hepatology (2013) 0.75
Virus C cure as a motivation for strong lifestyle change? Clin Gastroenterol Hepatol (2011) 0.75
Some processes of energy saving and expenditure occurring during ethanol perfusion in the isolated liver of fed rats; a Nuclear Magnetic Resonance study. BMC Physiol (2004) 0.75
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol (2002) 0.75
Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients, and kidney recipients. Gastroenterol Clin Biol (2002) 0.75
[Villo-glandular adenoma or polypoid dysplasia of esophagus: a case report]. Ann Pathol (2002) 0.75